Xembify - Correct Coding

On July 3, 2019, Xembify® (Grifols USA, LLC) was approved by the Food & Drug Administration (FDA). Xembify® is a 20% immune globulin solution for subcutaneous infusion through an external infusion pump for the treatment of primary immunodeficiencies (PI) in patients 2 years of age and older. Xembify® is included in the External Infusion Pumps Local Coverage Determination (LCD L33794).

Read the complete advisory article, Xembify - Correct Coding.

Last Updated: 06/23/2020